Heyu Biological Technology Corporation (HYBT) Stock
Heyu Biological Technology Corporation, alongside its subsidiaries, focuses on the research, development, and production of healthcare equipment. A key area of its present work involves developing the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber, a medical device intended for cancer treatment.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Heyu Biological Technology Corporation
Heyu Biological Technology Corporation, alongside its subsidiaries, focuses on the research, development, and production of healthcare equipment. A key area of its present work involves developing the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber, a medical device intended for cancer treatment. This innovative equipment is designed to induce cold nuclear fusion via cosmic ray muons within a contained environment to combat the disease. The company, incorporated in 1987 and headquartered in Xiamen, People's Republic of China, was formerly known as Pacific WebWorks, Inc., before adopting its current name, Heyu Biological Technology Corporation, in June 2018.
Heyu Biological Technology Corporation is headquartered in CN.
Heyu Biological Technology Corporation (HYBT) stock trades at $0.35 with a market capitalization of $361.36M. The stock is valued at a price-to-earnings (P/E) ratio of 175.00, price-to-book of 4.29, price-to-sales of 31.89. Over the past 52 weeks the stock has ranged between $0.00 and $3.40, and currently trades 89.7% below its 52-week high.
On profitability, Heyu Biological Technology Corporation generates a return on equity (ROE) of 2.41%, return on capital employed of 2.01%, an operating margin of 9.97%, a net profit margin of 8.85%.
Official website: heyubt.com